The case for & against
Bull & Bear analysis
Bullish
Astria Therapeutics, Inc. (NASDAQ: ATXS) is a biopharmaceutical company focused on the development of innovative therapies for hereditary angioedema (HAE) and atopic dermatitis. With its lead candidate STAR-0215 developed as a monoclonal antibody therapy for HAE, Astria aims to improve patient quality of life through reduced dosing burdens and enhanced efficacy. The company positions itself within the growing market for rare disease treatments, leveraging proprietary technology and patient-centric approaches.
Bull says
- ↑Astria ended Q3 2023 with $188.8M cash post $64M financing.
- ↑Phase 1A results support STAR-0215 dosing every 3 and 6 months.
- ↑90% of patients and 97% of HCPs likely to use 3-mo dosing.
- ↑Pivotal Phase 3 trial targeted for Q1 2025; STAR-310 IND due YE 2024.
- ↑High earnings yield and strong momentum factors suggest undervaluation.
- ↑Analyst revisions upward and favorable seasonality may boost stock.
Bear says
- ↓Placebo arm may slow Phase 3 enrollment, delaying pivotal results.
- ↓Takeda’s Takhzyro and Sanofi’s Dupixent intensify competitive pressure.
- ↓STAR-310 efficacy must surpass Dupixent in $26B dermatitis market.
- ↓Operating loss of $7.9M and high R&D burn strain cash.
- ↓Negative profitability and high volatility metrics raise downside risk.
- ↓Elevated short interest signals investor skepticism and price pressure.
Earnings Call · Q3 2021 · Mgmt. Guidance
Updated 09-04-2026bullish
Transcript signals
Bull points
- The introduction of YTE modifications in STAR215 were designed to extend plasma half-life and enable a long duration of action.
- we expect to file an IND for STAR-0215 mid-next year and to initiate a clinical program shortly thereafter.
- Our first objective was to identify a high-potency antibody that could inhibit plasmacalocrine to the same levels as lanodilumab, but with less antibody. And this has been achieved preclinically.
Bear points
- Our operating loss was $7.9 million in Q3 2021 compared to $10.9 million in Q3 2021.
- Our net loss was $7.9 or 61 cents per share in Q3.
Read full transcript analysis ›